CA3076094A1 - Mutated glycoprotein of vesicular stomatitis virus - Google Patents

Mutated glycoprotein of vesicular stomatitis virus Download PDF

Info

Publication number
CA3076094A1
CA3076094A1 CA3076094A CA3076094A CA3076094A1 CA 3076094 A1 CA3076094 A1 CA 3076094A1 CA 3076094 A CA3076094 A CA 3076094A CA 3076094 A CA3076094 A CA 3076094A CA 3076094 A1 CA3076094 A1 CA 3076094A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
protein
vsv
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3076094A
Other languages
English (en)
French (fr)
Inventor
Aurelie Albertini
Yves Gaudin
Helene Raux
Laura BELOT
Jovan Nikolic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60153233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3076094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA3076094A1 publication Critical patent/CA3076094A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3076094A 2017-09-22 2018-09-24 Mutated glycoprotein of vesicular stomatitis virus Pending CA3076094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306255.5 2017-09-22
EP17306255 2017-09-22
PCT/EP2018/075824 WO2019057974A1 (en) 2017-09-22 2018-09-24 GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS

Publications (1)

Publication Number Publication Date
CA3076094A1 true CA3076094A1 (en) 2019-03-28

Family

ID=60153233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3076094A Pending CA3076094A1 (en) 2017-09-22 2018-09-24 Mutated glycoprotein of vesicular stomatitis virus

Country Status (14)

Country Link
US (9) US12091434B2 (https=)
EP (3) EP4446337A3 (https=)
JP (2) JP7799945B2 (https=)
CA (1) CA3076094A1 (https=)
DK (1) DK3684786T3 (https=)
ES (1) ES2991089T3 (https=)
FI (1) FI3684786T3 (https=)
HR (1) HRP20241466T1 (https=)
HU (1) HUE069207T2 (https=)
LT (1) LT3684786T (https=)
PL (1) PL3684786T3 (https=)
PT (1) PT3684786T (https=)
SI (1) SI3684786T1 (https=)
WO (1) WO2019057974A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7799945B2 (ja) 2017-09-22 2026-01-16 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 変異型ウイルスタンパク質
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
JP7658584B2 (ja) * 2019-05-23 2025-04-08 マサチューセッツ インスティテュート オブ テクノロジー リガンドの発見およびレトロウイルス表面ディスプレーを介した遺伝子送達
US12311000B2 (en) 2019-08-16 2025-05-27 Mayo Foundation For Medical Education And Research Chimeric vesiculoviruses and methods of use
EP4087858A1 (en) * 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles
CN115768784A (zh) * 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
EP4182447A4 (en) * 2020-07-14 2024-10-23 Ichilov Tech Ltd. PSEUDOTYPED VIRUSES WITH CONFIGURATION FOR EXPRESSION OF CAR IN T CELLS
AU2022212952A1 (en) 2021-01-27 2023-08-10 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
JP2024513973A (ja) * 2021-04-16 2024-03-27 マサチューセッツ インスティテュート オブ テクノロジー 造血幹細胞のウイルスによる標的化
CA3238531A1 (en) * 2021-12-06 2023-06-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for discovery of receptor-ligand specificity by engineered cell entry
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
IL291148A (en) * 2022-03-06 2023-10-01 Noga Therapeutics Ltd Lentiviral vectors for in vivo targeting of hematopoietic cells
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
KR20250057777A (ko) 2022-07-25 2025-04-29 인테리우스 바이오테라퓨틱스, 인코포레이티드 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof)
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
KR20250121163A (ko) 2022-11-04 2025-08-11 우모자 바이오파마 인코포레이티드 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
TW202434735A (zh) 2022-11-04 2024-09-01 美商烏莫賈生物製藥股份有限公司 展示黏著分子融合的顆粒
TW202434621A (zh) 2022-11-04 2024-09-01 美商優莫佳生物製藥有限公司 多核苷酸構築體及相關病毒載體及方法
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2024196738A2 (en) * 2023-03-17 2024-09-26 Kelonia Therapeutics, Inc. In vivo daric
JP2026512079A (ja) * 2023-04-10 2026-04-14 深▲せん▼市済因生物科技有限公司 突然変異型の水疱性口内炎ウイルスｇ糖タンパク及びターゲティングベクター
WO2024216223A1 (en) 2023-04-12 2024-10-17 Vyriad Modular re-targeting of rhabdoviral (g) glycoproteins from their natural receptors
EP4713467A1 (en) 2023-05-15 2026-03-25 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
EP4735584A1 (en) * 2023-06-30 2026-05-06 The Children's Hospital of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry
CN121794390A (zh) * 2023-07-18 2026-04-03 维伟生物技术有限公司 纯化用树脂及其使用方法
AU2024325783A1 (en) * 2023-08-11 2026-02-26 Kelonia Therapeutics, Inc. Compositions for modifying cells
CN121844055A (zh) * 2023-08-16 2026-04-10 深圳市济因生物科技有限公司 一种病毒载体及其在感染b细胞中的应用
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025072615A1 (en) 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof
WO2025102013A1 (en) 2023-11-10 2025-05-15 Vyriad Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 深圳市济因生物科技有限公司 一种多肽及包含所述多肽基因的病毒载体
WO2025189142A1 (en) 2024-03-08 2025-09-12 Vyriad Membraned vesicles and purification methods thereof
WO2025212851A2 (en) 2024-04-03 2025-10-09 Orbital Therapeutics, Inc. mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
CN121045342A (zh) * 2024-05-31 2025-12-02 普米斯生物技术(苏州)有限公司 突变的水泡病毒包膜蛋白及其在慢病毒载体包装中的应用
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2025260074A1 (en) 2024-06-14 2025-12-18 Vyriad Multiplexing functional polypeptides and recombinant rhabdoviral g glycoproteins on enveloped delivery vehicles
WO2026006203A2 (en) 2024-06-24 2026-01-02 Orbital Therapeutics, Inc. Compositions and methods for making circular rna
WO2026006687A1 (en) 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148621A0 (en) * 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
WO2003066824A2 (en) 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
JP4411523B2 (ja) 2004-03-04 2010-02-10 株式会社日健総本社 抗ウイルス剤
US8008268B2 (en) * 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
PL2020444T3 (pl) 2007-08-03 2017-10-31 Pasteur Institut Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek
DK2185192T3 (en) 2007-08-03 2019-02-18 Pasteur Institut LENTIVIRAL TRANSFER VECTORS AND THEIR MEDICAL USES
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
BR112015013669A2 (pt) 2012-12-12 2017-11-14 Childrens Hospital Of Eastern Ontario Res Institute Inc composições e métodos para o tratamento de cânceres cerebrais
JP7799945B2 (ja) 2017-09-22 2026-01-16 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 変異型ウイルスタンパク質

Also Published As

Publication number Publication date
US12030915B2 (en) 2024-07-09
US12410216B2 (en) 2025-09-09
PL3684786T3 (pl) 2024-12-16
US12091434B2 (en) 2024-09-17
EP4446337A2 (en) 2024-10-16
EP3684786B1 (en) 2024-08-14
US12269848B2 (en) 2025-04-08
HUE069207T2 (hu) 2025-02-28
JP2020534007A (ja) 2020-11-26
US20240317811A1 (en) 2024-09-26
US12291551B2 (en) 2025-05-06
DK3684786T3 (da) 2024-10-28
WO2019057974A1 (en) 2019-03-28
US20240092839A1 (en) 2024-03-21
US12410215B2 (en) 2025-09-09
EP4446337A3 (en) 2025-01-08
EP3684786A1 (en) 2020-07-29
EP4442816A3 (en) 2025-01-08
US12297237B2 (en) 2025-05-13
US20250171505A1 (en) 2025-05-29
JP7799945B2 (ja) 2026-01-16
US20240327467A1 (en) 2024-10-03
US12264180B2 (en) 2025-04-01
JP2023179436A (ja) 2023-12-19
PT3684786T (pt) 2024-10-30
EP4442816A2 (en) 2024-10-09
US20200216502A1 (en) 2020-07-09
US20250171504A1 (en) 2025-05-29
HRP20241466T1 (hr) 2025-01-03
US20260078150A1 (en) 2026-03-19
US20240327466A1 (en) 2024-10-03
US20240317812A1 (en) 2024-09-26
FI3684786T3 (fi) 2024-11-04
LT3684786T (lt) 2024-11-11
ES2991089T3 (es) 2024-12-02
SI3684786T1 (sl) 2025-03-31

Similar Documents

Publication Publication Date Title
US12291551B2 (en) Mutated glycoprotein of vesicular stomatitis virus
US12203092B2 (en) Self-inactivating rabies virus vector encoding a nucleoprotein and degron
US12435111B2 (en) Mutant VSV ectodomain polypeptide and uses thereof
US10596264B2 (en) Peptides with viral infection enhancing properties and their use
CN115003328A (zh) 重组神经氨酸酶及其用途
HK40117176A (en) Mutated glycoprotein of vesicular stomatitis virus
HK40117175A (en) Mutated glycoprotein of vesicular stomatitis virus
ES2813827T3 (es) Péptidos que incluyen un dominio de unión de la subunidad de la fosfoproteína (P) viral a la nucleoproteína (N0) libre de ARN viral
US20260014249A1 (en) Enveloped virus like particles comrising sars-cov-2 s protein
Risco Quiroz Development of a Novel Strategy to Treat Spinal Muscular Atrophy
NZ752808A (en) Stabilized soluble prefusion rsv f polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230920

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240829

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240829

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241029

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250214

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250626

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250626

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260122

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260129

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260129